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Editors’ NotesNew Formats for a New Year
In addition to the recent redesign of our website, this month we’re making some changes to the designation of certain article
formats. As a result, you’ll see new names on two article types in this issue of Cell Stem Cell. Correspondence articles have
evolved over our first three volumes, changing from a conventional text-only format—now presented in CSC as ‘‘Letters’’—
into very short analyses (2000 words with a two-figure maximum). Therefore, this article type has been renamed ‘‘Brief
Report’’ to better reflect its scope, but these pieces will still appear in the front section of the journal, consistent with the intent
to cover topical issues of particularly strong current interest. In addition, Commentary articles have been renamed Perspec-
tives, and one appears in this issue. As with almost all of our article formats, including Research Articles, Reviews, Minire-
views, Forum articles, and even Letters, both Brief Reports and Perspectives will undergo external, anonymous peer review
prior to acceptance. A final change is that we’ve also made it even easier to contact an editor for advice about the suitability of
prospective submissions. You’ll now find an online ‘‘Presubmission’’ inquiry form on our website. Please don’t hesitate to get
in touch if you’d like some input as to whether your research or review article might be a strong candidate for Cell Stem Cell.
Looking beyond Roadblocks on the Path to Clinical Therapies
Born out of the same discussions that gave rise to the ISSCR’sGuidelines for theClinical Translation of StemCellspublished last
month (3: 607), Rao and colleagues offer their Perspective on a range of challenges facing thestandardized
production and clinical application of stem cells and their derivatives. This discussion pairs nicely with
a recent CSC review article from Kirouac and Zandstra (3: 369) that overviews more technical aspects
of scaling stem cell production. Meanwhile, steady experimental steps are being taken, and future clinical
applications of hESCs may build upon these. Also in this issue, Reh and colleagues report the functional
integration of hESC-derived retinal progenitors into visually impaired mice. While the extent of sensory
restoration remains incremental, the formation of light-responsive synaptic connections is a significant
step toward the goal of clinically relevant photoreceptor replacement.
The Complexity of Stress Responses
The careful balance of stem cell quiescence (to preserve function over time) and division (to maintain the stem cell pool as well
as give rise to differentiating progeny) is a central concept in our field. In this issue, Nimer and coauthors reveal that, in HSCs,
this equilibrium within cell-cycle progression is mediated at least in part by gene targets of the stress- and DNA-damage-
responsive oncogene p53. In the absence of p53, the proportion of quiescent HSCs decreases, and the pool of transplantable
HSCs is elevated. Interestingly, the observed impact of p53 appears to be independent of its cell-cycle-regulatory target p21
but likely does require the alternate targets Gfi-1 and Necdin. Also in this issue, Malhotra and Kincade review recent findings
that collectively reveal that Wnt signaling is another regulator of both proliferation and quiescence
in primitive hematopoietic cells, and that this pathway can also impact progenitor differentiation.
The range of Wnt ligands and inhibitors applied and the varying assays (both with and without
stress stimuli) used as functional read-outs in published accounts have led to significant contro-
versy and some confusion in the field. In their Review, the authors offer a model to begin to inte-
grate the findings of seemingly disparate reports. Stress signals impact stem cells outside of the
hematopoietic system as well. In the context of the Drosophila midgut, for example, Ip and
colleagues demonstrate that intestinal stem cells increase their rate of division in response to
tissue damage, and that this response is impacted by insulin receptor signaling.
Induced Pluripotent Stem Cells from Rats, Too
Despite the progress in finding chemical modifiers that increase the efficiency of iPSC generation, and the notable recent
success in isolating murine iPSCs without viral integration of the transduced reprogramming factors, clinical transplantation
of iPSCs or their differentiated progeny remains relatively distant on the horizon. More near-term utility of the reprogramming
process is found within the areas of disease modeling, candidate drug screening, and basic research efforts to improve our
understanding of how pluripotency is regulated. Toward this end, two Brief Reports published in this issue reveal that adult rat
somatic cells can also be reprogrammed to yield pluripotent cells that are capable of generating both teratomas and
chimeras. Liao et al. show that the same four factors that induce pluripotency in mouse and human fibroblasts are also suffi-
cient to reprogram primary rat cells. Ding and colleagues combine genetic transduction with altered culture conditions to
produce rat and human iPSCs that appear morphologically similar to murine ESCs. The specific signaling pathways impacted
by the addition of chemical inhibitors offer insight into the mechanisms that regulate pluripotency in multiple species, and the
availability of rat iPSCs provides an important resource for drug screening and animal modeling of diseases that cannot be
mimicked in murine systems.Cell Stem Cell 4, January 9, 2009 ª2009 Elsevier Inc. xi
